AbCellera Biologics Inc.

ABCL

$12.31

Updated: 24/09/2026, 05:36:03

Market Cap

$3.76B

Sector

Healthcare

Industry

Biotechnology

Country

Stock valuation chart

One-year closing share-price history for ABCL

Company Profile

AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.

USD

NASDAQ

CEO: Carl Hansen

Employees: 562

https://www.abcellera.com

Asset Summaries

Latest generated summaries for ABCL

No summaries found.

Detailed business

Structured knowledge from the latest official annual filing.

No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.

Full company information

Latest profile, trading, valuation, and identifier data stored for ABCL.

Share price: $12.31
Market cap: $3.76B
Exchange: NASDAQ
Currency: USD
CEO: Carl Hansen
Employees: 562
IPO date: 11/12/2020
Beta: 1.191
Last dividend: $0.00
Day range: $12.10 – $12.65
52-week range: $2.75 – $13.18
1-day performance: -2.69%
1-year performance: 348.45%
Current drawdown (1Y): -6.60%
CIK: 0001703057
CUSIP: 00288U106
ISIN: CA00288U1066
Created: 07/12/2025, 01:53:09
Last update: 24/09/2026, 05:36:03

Track AbCellera Biologics Inc. with an AI analyst

See which prediction-market events move ABCL, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Create a free account See what the world decides next

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News

News linked to ABCL from your Railway `news_articles` table.

AbCellera Biologics Inc. (NASDAQ:ABCL) Surges on Clinical Trial Success and Insider Confidence

Market Data • Market Data • 14/08/2026, 19:13:16

AbCellera: Q3 Hot Flashes Data Drop Aside, This Stock Is A Difficult Sell

Seeking Alpha • STOCK • 09/06/2026, 11:18:17

AbCellera Biologics Inc. (ABCL) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 05/06/2026, 17:12:58

AbCellera Biologics Bets on Hot Flash Antibody as Pipeline Pivot Gains Steam

MarketBeat • STOCK • 04/06/2026, 15:02:53

Has ABCELLERA BIOLG (ABCL) Outpaced Other Medical Stocks This Year?

Zacks Investment Research • STOCK • 01/06/2026, 12:42:32

Wall Street Analysts Believe ABCELLERA BIOLG (ABCL) Could Rally 97.28%: Here's is How to Trade

Zacks Investment Research • STOCK • 22/05/2026, 12:56:15

7 Healthcare AI Stocks Under $50 With Huge Upside Potential

24/7 Wall Street • STOCK • 18/05/2026, 09:35:19

Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year?

Zacks Investment Research • STOCK • 14/05/2026, 12:41:28

AbCellera Biologics Inc. (ABCL) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 14/05/2026, 02:20:47

AbCellera Biologics Q1 Earnings Call Highlights

MarketBeat • STOCK • 11/05/2026, 21:08:05

AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Beats Revenue Estimates

Zacks Investment Research • STOCK • 11/05/2026, 20:25:27

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

Business Wire • STOCK • 20/04/2026, 11:00:00